Mind Medicine (MindMed) Inc. (MNMD)
| Previous close | 8.35 |
| Open | 8.32 |
| Bid | 8.48 x 100 |
| Ask | 8.56 x 100 |
| Day's range | 8.32 - 8.72 |
| 52-week range | 2.41 - 12.22 |
| Volume | |
| Avg. volume | 2,427,406 |
| Market cap | 610.915M |
| Beta (5Y monthly) | 2.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.86 |
Business WireMindMed to Participate at May Investor Conferences
NEW YORK, May 09, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
Business WireNew Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
ATLANTA, May 09, 2024--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week in Atlanta.
Business WireMindMed Reports First Quarter 2024 Financial Results and Business Updates
NEW YORK, May 08, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
